Department of Pathology, Hospital of Vimercate, Vimercate, MB, Italy.
J Cell Physiol. 2010 Apr;223(1):14-26. doi: 10.1002/jcp.22011.
Src is a non-receptor cytoplasmic tyrosine kinase which becomes activated following the stimulation of plasma membrane receptors including receptor tyrosine kinases and integrins, and is an indispensable player of multiple physiological homeostatic pathways. Once activated, Src is the starting point for several biochemical cascades that thereby propagate signals generated extracellularly along intracellular interconnected transduction pathways. Src transmits signals promoting cell survival and mitogenesis and, in addition, exerts a profound effect on the reorganization of the cytoskeleton and the adhesion systems that underpin cell migration and invasion. Because increased activity of Src is a frequent occurrence in many types of human cancer, and because there is evidence of a prominent role of Src in invasion and in other tumor progression-related events such as epithelial-mesenchymal transition (EMT) and development of metastasis, inhibitors targeting Src are being viewed as promising drugs for cancer therapy.
Src 是一种非受体细胞质酪氨酸激酶，在受到包括受体酪氨酸激酶和整合素在内的质膜受体的刺激后被激活，是多种生理稳态途径中不可或缺的参与者。一旦被激活，Src 就是几个生化级联反应的起点，这些反应沿着细胞内相互连接的转导途径将细胞外产生的信号传递下去。Src 传递促进细胞存活和有丝分裂的信号，此外，它还对细胞迁移和侵袭所依赖的细胞骨架和黏附系统的重组产生深远影响。由于 Src 的活性增加是许多类型人类癌症的常见现象，并且有证据表明 Src 在侵袭以及其他与肿瘤进展相关的事件（如上皮-间充质转化（EMT）和转移发展）中发挥重要作用，因此针对 Src 的抑制剂被视为癌症治疗的有前途的药物。
